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Neuropathic pain is a drug resistant type of chronic pain and there is a strong medical demand to search for 
novel analgesically active compounds for its alleviation. In the present paper we investigated antihyperalge-
sic properties of 3-[4-(3-trifl uoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one (LPP1) in a mouse model 
of toxic polyneuropathy induced by a single intraperitoneal injection of oxaliplatin. Its infl uence on animals 
locomotor activity and motor coordination was also assessed using activity cages and rotarod apparatus, re-
spectively. Acute toxicity in neuropathic mice that received LPP1 was assessed, too. 
To demonstrate antihyperalgesic properties of LPP1 the cold plate test was used. In this assay the test com-
pound showed antihyperalgesic properties at doses of 1, 10 and 30 mg/kg, and these doses had no infl uence 
on animals’ locomotor activity or motor performance. A dose of 150 mg/kg completely abolished the animals 
locomotor activity (P<0.0001). The median effective dose (LD50) of LPP1 established in the acute toxicity test 
was 329.8 mg/kg.
In conclusion, basing on the results obtained it has been shown that LPP1 can be an interesting lead structure 
in the search for novel analgesics to be used for neuropathic pain syndromes.
Key words: Cold hyperalgesia, cold plate test, mice, oxaliplatin-induced painful toxic 
neuropathy
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INTRODUCTION
Neuropathic Pain Special Interest Group of the 
International Association for the Study of Pain 
(NeuPSIG) defi nes neuropathic pain (NP) as 
pain arising from a lesion or dysfunction of the 
central or peripheral nervous system. Nume-
rous possible causes of this condition comprise 
metabolic dysfunctions (diabetes mellitus), infec-
tious diseases (herpes simplex infections, human 
immunodefi ciency virus infections), mechani-
cal injuries of nerves or the use of anti-cancer 
drugs, such as vincristine, taxanes or platinum 
complexes [cisplatin, oxaliplatin (OXPT)] (UEDA, 
2006; SAŁAT et al., 2014c; SAŁAT et al., 2014d).
As chronic, non-receptor pain, NP is weakly 
sensitive to classical analgesic drugs, such as 
non-steroidal anti-infl ammatory drugs or opi-
oids, and it is estimated that 40-50% of patients 
are resistant to available pharmacotherapy 
(WATKINS et al., 2001). In view of the above, the 
treatment of NP is still a challenging endeavor 
and there is a strong medical demand to search 
for novel analgesically active compounds to be 
potentially used for pain relief in neuropathic 
patients. 
Previously, we demonstrated that 3-[4-(3-tri-
fluoromethyl-phenyl)-piperazin-1-yl]-dihydro-
furan-2-one (LPP1) has signifi cant analgesic, 
antiallodynic and antihyperalgesic properties 
in mouse models of acute (SAŁAT et al., 2012b; 
WIĘCKOWSKI et al., 2013), tonic (SAŁAT et al., 
2013a) and some neuropathic (SAŁAT and SAŁAT, 
2013; SAŁAT et al., 2014a) pain models. In the 
present research LPP1 is tested for its ability to 
attenuate cold hyperalgesia evoked by a single 
administration of OXPT. OXPT is a platinum 
anti-cancer drug which is frequently used in 
many malignant tumors. The effective treat-
ment with this drug is often limited because of 
its adverse effects, among which painful peri-
pheral toxic neuropathy is the most frequent rea-
son for therapy discontinuation (UMAPATHI et al., 
2005). OXPT-induced neuropathy is manifested 
by hypersensitivity to cold which is very often 
present in OXPT-treated patients and this ef-
fect is also observed in animals that receive this 
drug. Hence, in this study we assess the ability 
of LPP1 to reduce cold hyperalgesia in mice. In 
addition, the effect of LPP1 on locomotor activity 
and motor coordination of OXPT-treated mice is 




Male Albino Swiss (CD-1) mice weighing between 
18 g and 22 g were used in the experiments. The 
animals were kept in groups of 10 mice in cages 
at room temperature of 22 ± 2° C, under light/
dark (12:12) cycle, and they had free access to 
food and water before the experiments. The 
ambient temperature of the room and humid-
ity were kept constant throughout the testing. 
The animals destined for the experiments were 
randomly selected. Each group consisted of 8-10 
animals/dose. Immediately after the assay the 
animals were euthanized by cervical dislocation. 
Behavioral measures were scored by a trained 
observer blind to the experimental conditions. 
The experiments were performed between 8 a.m. 
and 3 p.m. All the procedures were approved by 
the Local Ethics Committee of the Jagiellonian 
University in Cracow (ZI/595/2011). 
Chemicals
LPP1 was synthesized at the Department of 
Physicochemical Drug Analysis, Chair of Phar-
maceutical Chemistry, Jagiellonian University 
in Cracow. For the behavioral tests it was pre-
pared in 0.9% saline (Polfa Kutno, Poland) and 
was injected intraperitoneally (i.p.) 30 min be-
fore each test. The doses of LPP1 used in in vivo 
assays were chosen on the basis of our previous 
preliminary data obtained for this compound in 
other pharmacological tests. Control mice were 
given 0.9% saline 30 min before testing. OXPT 
(Cayman Chemicals, USA) was prepared in 5% 
glucose solution and was administered to mice 
as a single i.p. dose of 10 mg/kg 3 hours before 
the fi rst measurement of the development of cold 
hypersensitivity. 
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Induction of cold hypersensitivity and 
measurement of the pain sensitivity threshold
The development of cold hypersensitivity induced 
by OXPT administration was assessed using the 
cold plate test. In order to compare the cold noci-
ceptive threshold in vehicle-treated control mice 
and OXPT-treated control animals, hind paw 
licking or lifting latencies in response to noxious 
cold stimulation (temperature of 4°C) were esti-
mated repeatedly 3 hours, then 1, 5, 6 and 7 days 
after OXPT injection. In this assay the cut off 
time of 60 s was established to avoid paw tissue 
damage (SAŁAT et al. 2013a). For the assessment 
of antihyperalgesic properties of LPP1 only mice 
with signs of neuropathy (i.e. OXPT-treated mice 
that showed reduced latencies of nocifensive re-
action in response to cold as compared with ve-
hicle-treated mice) were used. These mice were 
randomly divided into four groups which were 
fi rst tested for their baseline latencies of pain 
responses, and then they were treated with the 
test compound at doses of 1, 10, 30 or 50 mg/kg, 
and subjected again to the cold plate test.
The assessment of the cold nociceptive thresh-
old in mice was conducted using the cold plate 
apparatus (Bioseb, France) according to the 
method described recently (OSIKOWICZ et al., 
2009). Briefl y, on the day of the experiment the 
mice were placed individually on the apparatus 
supplied with a thermo-controller that was set 
up to keep the temperature of the plate constant 
at 4°C. The measurement of the pain reaction 
(lifting or licking the hind paw) was assessed as 
described above.
Infl uence on locomotor activity
The locomotor activity test was performed both 
in non-neuropathic mice and in OXPT-treated 
mice using activity cages (40 × 40 × 30 cm, sup-
plied with I.R. beam emitters), (Activity Cage 
7441, Ugo Basile, Italy ) connected to a counter 
for the recording of light-beam interrupts. For 
this test two doses of LPP1 were chosen: 30 mg/
kg (the highest dose that was effective in pain 
tests) and 150 mg/kg (the dose that was expec-
ted to induce severe neurological and behavioral 
impairments). Thirty minutes before the experi-
ment the mice were intraperitoneally pretreated 
with the test compound or the vehicle, and then 
they were individually placed in the activity 
cages in a sound-attenuated room. The animals 
horizontal and vertical movements (i.e. the num-
ber of light-beam crossings) were counted during 
the next 30 min of the test (SAŁAT et al., 2013b).
Infl uence on motor coordination
The test was performed according to the method 
described by SAŁAT et al. (2012a) with some mi-
nor modifi cations. The mice were trained daily 
for 3 days on the rotarod apparatus (Rotarod ap-
paratus, May Commat RR0711, Turkey; rod di-
ameter: 2 cm) rotating at a constant speed of 18 
rotations per minute (rpm). During each train-
ing session the animals were placed on a rotating 
rod for 3 min with an unlimited number of tri-
als. The proper experimentation was conducted 
at least 24 h after the fi nal training trial. On the 
test day, 30 min before the rotarod test the mice 
were intraperitoneally pretreated with the test 
compound (30 mg/kg – the highest analgesical-
ly active dose) or the vehicle. Then the animals 
were tested on the rotarod apparatus revolving 
at 6, 18, 24 rpm. Motor impairments, defi ned as 
the inability to remain on the rod for 1 min, were 
measured at each speed and were expressed as 
the mean time spent on the rotating rod. 
Assessment of acute toxicity
Acute toxicity was investigated in OXPT-treated 
mice according to the method described by LI-
TCHFIELD and WILCOXON (1949). Each experimen-
tal group consisted of 6 animals. Total mortal-
ity rate was assessed during the 72-hour period. 
Finally, the median lethal dose (LD50 value) was 
established (SAŁAT et al., 2012b). 
Data analysis
Data analysis of the in vivo results was provided 
by GraphPad Prism Software (v.5, San Diego, 
California, USA). The numerical results from 
behavioral tests were expressed as the means ± 
SEM (standard error of the mean). For the sta-
tistical evaluation of the results paired Student’s 
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t-test or one-way analysis of variance (ANOVA), 
followed by Dunnett’s post hoc comparison were 
used to compare the results obtained in drug-
treated and control groups. Repeated measures 
ANOVA, followed by Bonferroni post hoc com-
parison was applied for the statistical evaluation 
of time-courses of the development of cold hy-
peralgesia and locomotor activity. In every case 
P<0.05 was considered signifi cant. The median 
lethal dose (LD50) was calculated using the log-
probit method (LITCHFIELD and WILCOXON, 1949).
RESULTS
OXPT-induced cold hyperalgesia
The injection of OXPT resulted in a gradual de-
crease in the nociceptive threshold in these mice 
compared with their non-treated littermates 
(Fig.1). Since the statistically signifi cant reduc-
tion in the cold sensitivity threshold was ob-
served in all four experimental groups 3 hours 
Fig. 1. Development of cold hyperalgesia in response to temperature of 4°C measured using the cold plate test in mice 
treated with OXPT compared to pain reactivity of non-treated littermates. Results are shown as the mean latency time 
to pain reaction. Statistical analysis: repeated measure analysis of variance (ANOVA), followed by Bonferroni post hoc 
comparison. Signifi cance compared to mice not treated with OXPT (non-neuropathic mice): *** P<0.001; **** P<0.0001.
(a) Development of cold hyperalgesia in mice that subsequently served for the assessment of the antihyperalgesic properties 
of LPP1 (50 mg/kg) – drug effect: F[1,90]=55.67, P<0.0001; time effect: F[5,90]=8.13, P<0.0001; time x drug interaction: 
F[5,90]=8.20, P<0.0001.
(b) Development of cold hyperalgesia in mice that subsequently served for the assessment of the antihyperalgesic properties 
of LPP1 (30 mg/kg) - drug effect: F[1,18]=135.09, P<0.0001; time effect: F[5,90]=11.97, P<0.0001; time x drug interaction: 
F[5,90]=11.58, P<0.0001. 
(c) Development of cold hyperalgesia in mice that subsequently served for the assessment of the antihyperalgesic properties 
of LPP1 (10 mg/kg) - drug effect: F[1,18]=217.76, P<0.0001; time effect: F[5,90]=20.17, P<0.0001; time x drug interaction: 
F[5,90]=19.01, P<0.0001. 
(d) Development of cold hyperalgesia in mice that subsequently served for the assessment of the antihyperalgesic properties 
of LPP1 (1 mg/kg) - drug effect: F[1,18]=82.05, P<0.0001; time effect: F[5,90]=9.09, P<0.0001; time x drug interaction: 
F[5,90]=9.04, P<0.0001.
96 Sałat et al.
after OXPT injection, this time point was set up 
as acute hyperalgesia, while for the measure-
ment of late hyperalgesia the animals respon-
siveness 7 days after OXPT injection was used. 
Statistical analyses of data obtained for the de-
velopment of cold hyperalgesia were as follows: 
for mice that were subsequently used to assess 
the antihyperalgesic properties of LPP1 at a dose 
of 1 mg/kg (Fig.1a) – drug effect: F[1,18]=82.05, 
P<0.0001; time effect: F[5,90]=9.09, P<0.0001; 
time x drug interaction: F[5,90]=9.04, P<0.0001. 
For mice that were used to assess the antihyper-
algesic properties of LPP1 at 10 mg/kg (Fig.1b) 
– drug effect: F[1,18]=217.76, P<0.0001; time ef-
fect: F[5,90]=20.17, P<0.0001; time x drug inter-
action: F[5,90]=19.01, P<0.0001. For mice that 
subsequently served for the assessment of the 
antihyperalgesic properties of LPP1 at a dose of 
30 mg/kg (Fig. 1c) – drug effect: F[1,18]=135.09, 
P<0.0001; time effect: F[5,90]=11.97, P<0.0001; 
time x drug interaction: F[5,90]=11.58, P<0.0001, 
and for mice that were used to assess the antihy-
peralgesic properties of LPP1 (50 mg/kg; Fig. 1d) 
– drug effect: F[1,90]=55.67, P<0.0001; time ef-
fect: F[5,90]=8.13, P<0.0001; time x drug interac-
tion: F[5,90]=8.20, P<0.0001.
Antihyperalgesic activity of LPP1
The antihyperalgesic activity of LPP1 at doses 
of 1, 10, 30 and 50 mg/kg was assessed twice: 3 
hours and 7 days after OXPT (Fig. 2). The dose 
of 1 mg/kg had antihyperalgesic properties 7 
days after OXPT (signifi cant at P<0.05), but not 
3 hours after OXPT (Fig. 2a). The dose of 10 mg/
kg elevated the pain threshold only in the acute 
phase (signifi cant at P<0.05; Fig. 2b). The dose 
of 30 mg/kg showed antihyperalgesic proper-
Fig. 2. Antihyperalgesic activity of LPP1 in OXPT-treated neuropathic mice measured using the cold plate test at two time 
points: 3h and 7 days after OXPT injection. Results are shown as the mean latency time to pain reaction (licking or lifting 
the hind paw) in response to cold (temperature of 4° C). Statistical analysis: paired Student’s t-test: *P<0.05, **P<0.01 (vs. 
baseline latency of neuropathic mice – i.e., latency before the test compound’s administration).
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ties 3 hours (signifi cant at P<0.05) and 7 days 
(signifi cant at P<0.01) after OXPT administra-
tion (Fig. 2c). The dose of 50 mg/kg did not de-
monstrate antihyperalgesic activity either in the 
acute phase or in the late phase (Fig. 2d). 
Infl uence on locomotor activity
In the locomotor activity test the infl uence of 
LPP1 (30 mg/kg and 150 mg/kg) on animals loco-
motor activity was assessed in neuropathic mice 
and compared with that of non-neuropathic and 
OXPT-treated neuropathic controls (Fig. 3). The 
dose of 30 mg/kg had no effect on animals loco-
motor activity (data not shown), but the dose of 
150 mg/kg completely abolished animals locomo-
tor activity (P<0.0001). The locomotor activity of 
OXPT-treated control mice was only slightly re-
duced as compared with non-neuropathic control 
mice, and these differences were not statistically 
signifi cant (Fig. 3).
Infl uence on motor coordination
In the rotarod test at 6, 18 or 24 rpm LPP1 at a 
dose of 30 mg/kg did not induce motor coordina-
tion impairments in OXPT-treated mice. 
Fig. 3. Infl uence of LPP1 at the dose of 150 mg/kg on 
locomotor activity of OXPT-treated mice compared to non-
neuropathic and OXPT-treated controls. Results are shown 
as mean number of light beam crossings in control mice and 
LPP1-treated mice. Statistical analysis: repeated measure 
analysis of variance (ANOVA), followed by Bonferroni post 
hoc comparison. Signifi cance compared to OXPT-treated 
control mice: ****P<0.0001. Drug effect: F[4,25]=38.17, 
P<0.0001; time effect: F[4,100]=5.87, P<0.001; time × drug 
interaction: F[16,100]=2.38, P<0.01.
Assessment of acute toxicity
To assess acute toxicity of LPP1 its LD50 equal 
to 329.8 mg/kg (254.1-428.0) was established in 
OXPT-treated neuropathic mice. This value was 
approximately twice as low as the previously es-
tablished LD50 value for LPP1 in non-neuropa-
thic mice (SAŁAT et al., 2012b).
DISCUSSION
The aim of the present research was to establish 
an antihyperalgesic effect of a novel dihydrofu-
ran-2-one derivative, the compound LPP1, in a 
mouse model of OXPT-induced painful toxic neu-
ropathy. Previously we demonstrated signifi cant 
antinociceptive properties of LPP1 in rodent 
models of acute (SAŁAT et al., 2009; SAŁAT et al., 
2012b), tonic (SAŁAT et al., 2013a) and diabetic 
neuropathic pain (SAŁAT et al., 2013a; SAŁAT and 
SAŁAT, 2013). This compound also showed strong 
local anesthetic properties in models of local an-
esthesia in guinea pigs (SAŁAT et al., 2009), and 
it had antioxidant capacity in vitro and ex vivo 
(SAŁAT et al., 2012b; SAŁAT et al., 2014b). These 
results suggest that both the cell membrane-sta-
bilizing activity and the reactive oxygen species-
scavenging activity may contribute to pharma-
cological effects caused by this compound and 
observed in vivo.
The ability of LPP1 to attenuate OXPT-
evoked hyperalgesia was assessed using the cold 
plate test as OXPT induces hypersensitivity to 
cold both in patients treated with this drug and 
in experimental animals. OXPT is an anticancer 
drug which induces the formation of DNA cross-
links causing apoptotic death of dividing cells, 
but it has also affi nity for the peripheral nervous 
system. In rodents a single injection of OXPT 
induces painful peripheral neuropathy accom-
panied by tactile allodynia (pain induced by nor-
mally innocuous stimuli) and cold hyperalgesia 
(NASSINI et al., 2011; RENN et al., 2011), but not 
heat hyperalgesia (XIAO et al., 2012). 
At doses of 1-30 mg/kg LPP1 prolonged the 
latency of nocifensive reaction in response to 
cold stimulus, which indicates that it has anti-
hyperalgesic properties in vivo. Recently, it has 
been shown that cold hyperalgesia in rodents 
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treated with OXPT is mediated by the Transient 
Receptor Potential cation channel subfamily A, 
member 1 (TRPA1) stimulation (NASSINI et al., 
2011; ZHAO et al., 2012). ZHAO et al. (2012) dem-
onstrated that a single dose of OXPT induces 
cold hypersensitivity associated with enhanced 
responsiveness of TRPA1 but not with other 
transient receptor potential channels. Although 
the precise mechanism of TRPA1 contribution to 
OXPT-induced cold hyperalgesia is not clear, its 
role as a sensor for electrophilic, reactive com-
pounds, such as reactive oxygen species, is well 
established (NASSINI et al., 2011). In our earlier 
research the blockade of TRPA1 as a potential 
mechanism of action of LPP1 was demonstrat-
ed (SAŁAT et al., 2014a). Due to its antioxidant 
capacity, LPP1 might also indirectly inhibit 
TRPA1, resulting in the profound attenuation of 
OXPT-evoked hypersensitivity to cold. 
The mechanisms underlying the observed 
dose- and time-dependent responses of LPP1-
treated mice to cold stimulus are not clear and 
they require further studies. The lack of effi cacy 
of LPP1 at a dose of 10 mg in the late phase of 
cold hyperalgesia, and the lack of antihyperalge-
sic activity of LPP1 at 1 mg/kg in the acute phase 
are diffi cult to explain but this observation sug-
gests that early and late phases of OXPT-induced 
hyperalgesia are mediated by two distinct me-
chanisms which are not equally sensitive to vari-
ous doses of this analgesically active compound.
In this research the infl uence of the compound 
LPP1 on neuropathic animals locomotor activity 
was also investigated. For this purpose two doses 
were chosen – the dose of 30 mg/kg which was the 
highest analgesically active dose of LPP1, and 
the dose of 150 mg/kg. In our previous research 
we observed that doses up to 100 mg/kg had no 
infl uence on animals motor skills, while doses 
higher than 100 mg/kg might induce neurologi-
cal and behavioral defi cits. In the present study 
for the dose of 150 mg/kg a signifi cant reduction 
in animals’ locomotor activity was demonstrated. 
This may suggest sedative properties of this com-
pound in vivo, but it should be emphasized that 
this effect was observed only for the dose of 150 
mg/kg, and sedation was not observed for analge-
sically active low doses. This is an important fact 
as it is well known that compounds with seda-
tive properties may give false positive results in 
pain tests. Similarly, drug-induced motor defi cits 
may also be responsible for these false positive 
results. In view of the above, the effect of LPP1 
at the analgesically active dose (30 mg/kg) on 
OXPT-treated animals’ motor coordination was 
assessed using the rotarod test. The results ob-
tained confi rmed that this compound did not in-
duce motor impairments at doses that were ef-
fective in pain tests.
The studies to assess acute toxicity of LPP1 
in OXPT-treated mice resulted in the establish-
ment of the LD50 value after i.p. administration 
which was 329.8 mg/kg. In our earlier research 
the LD50 value in mice without neuropathy was 
established (748 mg/kg) (SAŁAT et al., 2012b). In 
view of the above, it can be concluded that OXPT 
co-administered with LPP1 increases its toxicity 
in mice as the LD50 value in neuropathic mice is 
more than twice as low as that found for their 
non-neuropathic littermates. 
To conclude, in this study a signifi cant antihy-
peralgesic effect of a novel derivative of dihydro-
furan-2-one was demonstrated. This compound 
effectively attenuated cold hyperalgesia induced 
by OXPT at doses much lower than the doses 
causing acute toxic effects. This indicates that 
LPP1 might be a very interesting lead structure 
in the search for analgesics used in neuropathic 
patients.
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